Marksans Pharma share news, announcements and annual reports
NSE: MARKSANSBSE: 524404Pharmaceuticals & BiotechnologySmall Cap
Marksans Pharma Limited · Formerly Tasc Pharmaceuticals · Face value ₹1 Face value. The nominal value of one share as the company issued it, the unit its share capital is counted in and a dividend can be stated as a percentage of; it has no link to the share price. Face value in the glossary · Listed Feb 1994 on BSE, Jan 2002 on NSE
Last close ₹315.35up ₹10.15 (3.33%)BSE ₹315.10
Share price at the NSE close on 29 Oct 2026. Previous close ₹305.20.
29 Oct: open ₹305.90, high ₹318.80, low ₹300.00
52-week range of traded prices to 29 Oct 2026
₹155.00Low, 30 Mar 2026₹350.95High, 24 Sep 2026
- Next results date: the board meets on 4 Nov 2026 to consider: financial results. The notice · Results calendar
- Market capMarket capitalisation. Share price times the number of shares: what the whole company is worth at the day's price. The rank is by average market value over the six months to Jun 2026, among listed companies. Market capitalisation: how it is worked out
- ₹14,291 Cr592nd largest listed
- P/EPrice to earnings, trailing. Market cap divided by the profit of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, after the share of the other owners of its subsidiaries: what investors pay for each rupee of a year's profit. Price to earnings, trailing: how it is worked out
- 27.65
- P/BPrice to book. Market cap divided by the net worth that belongs to the company's own shareholders, its assets less everything it owes and less the other owners' share of its subsidiaries, on its latest balance sheet. Price to book: how it is worked out
- 4.73
- Dividend yieldDividend yield. Dividends paid per share in the twelve months to the day, as a percentage of the day's share price.
- 0.29%
- ROEReturn on equity. Profit over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, as a percentage of their net worth, the money they have in the business. Net worth is the latest balance sheet's; the one a year before is not on record.
- 17.1%
- ROCEReturn on capital employed. Operating profit after depreciation (revenue less operating expenses and depreciation, without other income and one-off items) as a percentage of all the money the business runs on: the whole group's net worth, the other owners of its subsidiaries included, plus borrowings. Lease liabilities are not counted: the results filings do not state them. The profit is over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly); net worth and borrowings are on the latest balance sheet.
- 19.9%
- Debt to equityDebt to equity. Borrowings divided by the whole group's net worth, the other owners of its subsidiaries included: rupees borrowed for each rupee of equity in the business. Lease liabilities are not counted: the results filings do not state them. From the balance sheet at the end of Mar 2026.
- 0.01
- Volume, NSEVolume. Shares traded on the last trading day; delivery is the part buyers kept rather than sold again the same day. Volume in the glossary
- 20,08,91538.7% delivered
Marksans Pharma share news and announcements
683 announcements, routine notices left out, newest first. Page 14 of 14.
Jul 2008
29 Jul · Updates
Company has received Certificate of suitability of Metformin Hydrochloride drug substance from the European Directorate for the Quality of Medicines and Healthcare (EDQM). The further details of the same shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.18 Jul · Board meeting
To consider the following business : 1) To take on record Un-audited (Provisional) quarterly results for the quarter ended June 30, 2008. 2) Any other business with the permission of the Chair.
May 2008
23 May · Limited Review Report
Auditor's have conducted the limited review of the unaudited financial results for the period ended March 31, 2008 and found the same to be in order subject to certain observations. The auditor's observations are: "The Company will provide for Deferred Income Tax at the year end."
Apr 2008
23 Apr · Board meeting
To consider the following business: 1) to take on records Un-audited (Provisional) quarterly results for the quarter ended March 31, 2008. 2) Any other business with the permission of the Chair.
Mar 2008
28 Mar · Board meeting
At the meeting of the Board of Directors of the Company held on 27th March,2008, it was decided to redeem 13,50,000 Redemption Cumulative Redeemable Preference Shares of Rs.100/- each issued by the Company in March, 2003 and due for redemption on 27.03.2008 by way of issue of Cumulative Redeemable Preference Shares for the same amount as due for redemption and on the same terms and conditions as earlier. The said shares will be due for redemption on 27th March, 201326 Mar · Board meeting
To consider and approve redemption of Cumulative Redeemable Preference Shares issued by the Company and due for redemption on March 27, 2008 by way of issue of Cumulative Redeemable Preference Shares for the same amount as due for redemption and on the same terms and conditions as earlier.
Feb 2008
29 Feb · Results
Results of the postal ballot declared on February 29, 2008. Further the Company has submitted to the Exchange the copy of the Scrutinizer's report. The copy of the same alongwith the details of Results of postal ballot shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.29 Feb · Corporate action
Board of Directors at their meeting held on February 29, 2008 have decided Book Closure Dates as from March 18, 2008 to March 25, 2008 (both days inclusive) for the purpose of sub-division of the Equity Shares of the Company from Rs. 10/- per share to Re. 1/- per share. Further the Company has submitted to the Exchange the copy of the shareholder's resolution declared through postal ballot approving sub-division of shares. The copy of the same shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.27 Feb · Board meeting
To declare the results of the postal ballot and to decide the record date for the purpose of sub - division of the Equity shares of the Company.8 Feb · Meeting
In accordance with the provisions of Section 192A of the Companies Act, 1956 read with the Companies (Passing of the Resolution by Postal Ballot) Rules, 2001, the following Resolutions are to be approved by the Members of the Company by Postal Ballot: 1) Sub Division of Shares; 2) Increase in Authorised Share Capital; 3) Increase in Borrowing Power; 4) Creation of Charge; 5) Issue of Securities. The Company has appointed Mr. Ashish Kumar Jain of M/s. A.K. Jain & Co., Practising Company Secretaries as Scrutinizer for the purpose of Postal Ballot exercise. The duly completed postal ballot forms should reach the Company not later than the close of working hours on February 28, 2008. The result of the Postal Ballot shall be announced by the Chairman, or in his absence by any other person, so authorized by the Chairman on February 29, 2008. A copy of Notice of Postal Ballot shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.
Jan 2008
25 Jan · Corporate action
At the Board Meeting of the Company held on January 25, 2008 following decision were taken. (1) Sub division of the Equity Shares Capital of the Company from Rs.10/- per share to Rs.1/- per share. Further the Company has informed regarding Outcome of Board Meeting of the Company held on January 25, 2008. The details of the Outcome of Board Meeting shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.15 Jan · Change in registered office
Change of address of the Registered office of the Company from 601-622, Chintamani Plaza, Mohan Studio Compound, Andheri-Kurla Road, Andheri (E), Mumbai 400 099 to 21st Floor, Lotus Business Park, Off New Link Road, Andheri (W), Mumbai 400 053."8 Jan · Board meeting
To consider the following business: 1) To take on records Un-audited (Provisional) quarterly results for the quarter ended December 31, 2007. 2) To consider Sub division of the Equity Shares capital of the Company. 3) Any other business with the permission of the Chair.7 Jan · Business
"Marksans Pharma Limited's subsidiary, Marksans Pharma (UK) Limited, has entered into a definitive agreement to acquire 100% of the share capital of Hale Group Limited, the parent company of Bell, Sons & Co (Druggists) Limited ("Bell"). Through this acquisition, Marksans will have access to 34 product licenses of Bell, situated near Liverpool, in the UK". The details of the same shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.
Dec 2007
31 Dec · Business
At the Board meeting of the Company held on 31st December, 2007 following decisions were taken: 1) Consent of the Board of Directors of the Company for entering into Share Purchase Agreement with Hale Group Limited, U.K. for acquiring its entire share capital along with its subsidiary Company Bell, Sons & Co. (Druggists) Limited and authority to Mr. Mark Saldanha, Managing Director to execute the same. The above acquisition shall be through Companies 100% subsidiary, Marksans Pharma U.K. Limited; 2) Shifting the Registered office of the Company from 601-622, Chintamani Plaza, Mohan Studio Compound, Andheri- Kurla Road, Andheri (E), Mumbai 400 099 to 21st Floor, Lotus Business Park, Off New Link Road, Andheri (W), Mumbai 400 05324 Dec · Management
The Company has received a letter from Mr.Ajay Mittal, intimating his resignation from the Directorship of the Company with effect from 24th December, 20073 Dec · Legal
With regard to the news published in the leading news paper regarding proposed acquisition by the Company of UK based OTC firm, this is to clarify that the Company is looking for inorganic growth opportunity in India as well as outside India. For the same, Company is in the process of dialogues and participation in the bidding processes. Company has also appointed, various Investment banking firms for the same purpose. However, so far, company has not entered into any definitive share subscription agreement for the acquisition.
Nov 2007
22 Nov · Limited Review Report
Auditor's have conducted the limited review of the unaudited financial results for the period ended September 30, 2007 and found the same to be in order subject to certain observations. The auditor's observations are: "The company will provide for Deferred Income Tax at the year end."22 Nov · Miscellaneous
The Company has received a recognition letter from Government of India, Ministry of Science & Technology Department of Scientific and Industrial Research, New Delhi recognizing R&D Unit (s) of the Company at Verna, located at Verna Electronic City, Verna, Goa
Oct 2007
17 Oct · Board meeting
To consider the following business: 1) To take on records Un-audited (Provisional) quarterly results for the quarter ended September 30, 2007. 2) Any other business with the permission of the Chair.3 Oct · Meeting
Minutes of the Annual General Meeting of the members of the Company held on September 27, 2007. A copy of the same shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.
Sep 2007
27 Sep · Meeting
Outcome of the Annual General Meeting of the company held on September 27, 2007. The details of the business transacted at the AGM shall be available on the NSE website (http://www.nseindia.com) under Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.26 Sep · Miscellaneous
Company has received Certificate of suitability for Ciprofloxacin Hydrochloride drug substance from the European Directorate for the Quality of Medicines and Healthcare (EDQM). The details of the same shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.3 Sep · Meeting
At the meeting of the Board of Directors of the Company held on August 31, 2007, the following decision were taken :- 1) Appointment of Statutory Auditors of the Company. 2) Adoption of the Notice of the Annual General Meeting. 3) Fixation of the day, date, time and place of the Annual General Meeting. 4) Fixation of the book closure dates for the purpose of the Annual General Meeting. Company has fixed book Closure dates from September 21, 2007 to September 27, 2007 (both days inclusive), for the purpose of the Annual General Meeting. Further, the Company has informed that the Annual General Meeting of the Company will be held on September 27, 2007.
Aug 2007
28 Aug · Board meeting
To consider and adopt: 1) Audited Annual Accounts of the Company for the year ended March 31, 2007 along with Auditors report, Directors report, Corporate Governance Report and management Analysis and Discussion report. 2) To consider appointment of Statutory Auditors of the Company. 3) To approve the draft notice of the Annual General Meeting. 4) Fix the day, date, time and place of the Annual General Meeting. 5) To fix the book Closure dates for the purpose of the Annual General Meeting. 6) Any other business with the permission of the Chair.
Jul 2007
20 Jul · Board meeting
To consider the following business: (1) To take on records Un-audited (Provisional) quarterly results for the quarter ended June 30, 2007. (2) Any other business with the permission of the Chair.
Jun 2007
7 Jun · Limited Review Report
Auditor's have conducted the limited review of the unaudited financial results for the period ended March 31, 2007 and found the same to be in order subject to certain observations. The auditor's observations are: "That the company will provide for Income Tax - deferred at the year end."
Apr 2007
19 Apr · Board meeting
To consider the following business: 1) To take on records Un-audited (Provisional) quarterly results for the quarter ended March 31, 2007. 2) Any other business with the permission of the Chair.
Mar 2007
20 Mar · Limited Review Report
Auditor's have conducted the limited review of the unaudited financial results for the period ended December 31, 2006 and found the same to be in order subject to certain observations. The auditor's observations are: "that the company will provide for Income Tax - deferred at the year end."
Feb 2007
15 Feb · Business
Hon. High Court, Mumbai, has ordered Amalgamation of Mark Remedies Limited (a 100 % Subsidiary of Marksans Pharma Limited) with Marksans Pharma Limited13 Feb · Management
Mr. Atul P. Vyas, has resigned from the Directorship of the Company8 Feb · Management
Dr. A.V. Sharma, has resigned from the Directorship of the Company.
Jan 2007
22 Jan · Board meeting
To consider the following business: 1) To take on records Un-audited (Provisional) quarterly results for the quarter ended December 31, 2006. 2) Any other business with the permission of the Chair.